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Abstract
Objective: To investigate the effectiveness of high-voltage monophasic
pulsed current (HVMPC) as an adjunct to a standard wound care for the
treatment of Stage II and III pressure ulcers (PrUs).
Design: Prospective, randomized, double-blind, controlled clinical study.
Setting: Two nursing and care centers.
Patients: Patients with PrUs that did not respond to previous treatment for
at least 4 weeks were randomly assigned to the electrical stimulation (ES)
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group (25 patients; mean age of 79.92 ± 8.50 years; mean wound surface
area [WSA] of 10.58 ± 10.57 cm2) or to the control group (24 patients;
mean age of 76.33 ± 12.74 years; mean WSA of 9.71 ± 6.70 cm2).
Interventions: Both the ES and control groups received standard wound
care and respectively, cathodal HVMPC (154 microseconds; 100 pulses per
second; 0.24 A; 250 µ/s) applied continuously for 50 minutes once a day, 5
times a week, or sham HVMPC.
Main Outcome: Percentage area reduction over 6 weeks of intervention.
Main Results: In the ES group, there was a statistically significant decrease
in WSA after 1 week of treatment (35% ± 30.5%) compared with 17.07% ±
34.13% in the control group (P = .032). After treatment, at week 6,
percentage area reduction in the ES group was 80.31% ± 29.02% versus
54.65% ± 42.65% in the control group (P = .046).
Conclusions: Cathodal HVMPC reduces the WSA of Stage II and III PrUs.
The results are consistent with the results of other researchers who used
HVMPC to treat PrUs.
Keywords: high-voltage monophasic pulsed current wound healing;
pressure ulcers; electrical stimulation

Introduction
Pressure ulcers (PrUs) are a clinical problem for patients and
medical personnel all over the world. The treatment of PrUs is, in
most cases, a long process involving the application of various
frequently costly interventions. It is therefore important to develop
new methods that effectively promote and accelerate the healing of
these intractable wounds. One of the methods used to treat PrUs is
electrical stimulation (ES), which is recommended by the clinical
practice guidelines as appropriate for treating chronic Stage II, III,
and IV PrUs.1,2

The Evidence Supporting Electrical Stimulation
for Wound Healing
The authors of meta-analyses and reviews published in recent
years point to the positive effect of ES on the healing of chronic
wounds.3–5 The systematic review of 174 studies (randomized trials
and comparative observational studies) on different PrU treatment
strategies in adults that Smith et al.3 performed in 2013 showed
moderately consistent results from 1 good-quality and 8 fair-quality
trials, each of which presented ES as a biophysical energy capable of
improving PrU healing rates. In the same year, Thalkral et al.4
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reviewed 16 randomized clinical trials (RCTs) in which ES was used to
treat wounds. They concluded that ES decreased bacterial infection,
increased local perfusion, and accelerated wound healing. It is also
noteworthy that none of the available studies mentions device-related
complications or adverse effects of the electric field energy. In 2014,
Koel and Houghton5 systematically analyzed 15 ES studies with clear
randomized controlled design and published their findings of healing
rate expressed as percentage area reduction (PAR) over 4 weeks of
treatment. They concluded that applying additional monophasic ES to
a program of standard wound care (SWC) increases the reduction of
PrU area in 4 weeks of treatment by an extra 42.7% (95% confidence
interval, 32.0–53.3).

Types Of Electrical Currents And Treatment
Parameters
The range of electric currents used in wound treatment
research varies from low-intensity direct current6,7 (LIDC; <1.0 mA),
microamperage current8–10 (very low current imitating natural current
of injury applied at subsensory level9), low-voltage biphasic pulsed
current (LVBPC),11–13 low-voltage monophasic pulsed current
(LVMPC),14–19 and high-voltage monophasic pulsed current
(HVMPC).20–27 In 2014, Houghton28 published a systematic review of
32 clinical studies on LIDC, microamperage current, LVBPC, and
LVMPC, and Polak et al.29 performed a critical review of 11 clinical
studies on chronic wounds treated with HVMPC. Both authors28,29
reported that ES protocols involving the use of LVBPC,28 LVMPC,28 and
HVMPC29 were capable of producing consistently positive results in
patients with chronic wounds. In the opinions of those authors,28,29
the ES-induced improvement in wound healing depends on the type
of ES waveform and the particular methodology used, but the optimal
parameters of the stimulus and the ES schedule for chronic wounds
still need to be defined.
In the RCTs, monophasic HVMPC was used to treat venous leg
ulcers (VLUs),22,24 PrUs,20,21,25–27 and diabetic foot ulcers (DFUs).23 In
all of cited studies, HVMPC was applied for designated time periods
with SWC (the latter intervention was necessary for ethical reasons).
The results were compared with the effects of treatment in the control
groups that respectively received only SWC22,25–27 or SWC and sham
HVMPC.20,21,23,24 Authors of all cited studies indicated that HVMPC
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promoted wound healing because the wound surface area (WSA) in
the SWC + HVMPC groups decreased more than that in the control
groups.20–27
The parameters of HVMPC used in all cited studies were similar.
The authors reported using twin-peak monophasic pulses20–27 with a
pulse duration of 100 microseconds20,22–24,26,27 or 50 microseconds25
and pulse frequency of typically 100 pulses per second (pps)21,22,24–29
or 105 pps,20 at which the current evoked only submotor sensory
perception.20–27 Electrical stimulation involving HVMPC was usually
applied for a total of 3.75 to 7 hours a week.20–22,24,26,27 In most cases,
treatment sessions of 45 to 60 minutes were held daily, 5 to 7 days a
week.20–22,24,26,27 Both electrodes were placed on a conductive saline,
moist gauze, or on a wafer hydrogel dressing. The treatment
electrode was placed on the wound surface,20–27 and the return
electrode was attached to healthy skin at least 15 to 20 cm away.20–
22,24,26,27

The authors of the published studies used different treatment
electrode polarities. In some cases, treatment started with cathodal
stimulation that was continued over the whole length of the trial or
was applied at the initial stage only. Griffin et al.21 and Houghton et
al.24 had good results treating PrUs21 and VLUs24 using only the
cathode. In the first of the 2 studies,21 Stage II through IV PrUs in the
ES group (SWC + ES) demonstrated significantly greater percentageof-change decrease in WSA from their pretreatment size than did
ulcers in the control group (SWC + sham ES) at days 5, 15, and 20 (P
< .05).21
In the second study,24 by week 4, WSA in the ES group (SWC +
ES) decreased by 44.3% compared with only 16% in the control
group (SWC + sham ES) with P < .05. In another study conducted by
Houghton et al,25 PrUs (mostly Stage III and IV) were stimulated with
the cathode in the first week, and then polarity was reversed every
week until the end of the 12-week treatment period. Percentage area
reduction of PrUs was evaluated at weeks 1, 2, and 3. There was
significantly less WSA from baseline in the ES group (SWC + ES) than
in the control group (SWC alone) at month 3 (P = .048). Franek et
al.22,26 and Polak et al.27 too, started the treatment of VLUs22 and
PrUs26,27 with cathodal stimulation that was continued for the first 1 to
3 weeks depending on the growth of granulation tissue. When at least
Advances in Skin & Wound Care, Vol 29, No. 10 (October 2016): pg. 447-459. DOI. This article is © Wolters Kluwer Health,
Inc. and permission has been granted for this version to appear in e-Publications@Marquette. Wolters Kluwer Health,
Inc. does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express
permission from Wolters Kluwer Health, Inc.

5

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

50% of the wound surface was covered with granulation tissue, the
anode was introduced as the treatment electrode until the end of
treatment that lasted 6 weeks22,26 and 4 weeks,27 respectively. The
authors of the first study22 reported that after 2 weeks of cathodal
stimulation the granulation tissue area in VLUs was significantly
greater (P < .003) in the ES group (SWC + ES) than in the control
group (SWC alone) and that 6 weeks of treatment decreased the area
of VLUs more in the ES group (the decrease was not significant, P
> .05) than in the control group.22 The results obtained by the
authors of the second study26 involving Stage II and III PrUs were
slightly different. The ES group (SWC + ES) and the control group
(SWC alone) were similar in the area of granulation tissue over the
whole period of treatment (P > .05), but after 6 weeks of treatment,
PAR in the ES group was greater than that in the control group (P
= .00003).26 The authors of the third study27 (a preliminary trial with
a sample of only 22 patients with Stage II and III PrUs) recorded that
percentage decrease in PrU area after 4 weeks of treatment was
significantly greater in the ES group (SWC + ES) than that in the
control group (SWC alone) with P = .0079 (they did not record the
area of granulation tissue). The methodology that Kloth and Feedar20
followed to apply cathode and anode as the treatment electrodes was
considerably different from the methodologies used in the presented
studies. They stimulated Stage IV PrUs with the anode and reversed
polarity to negative only if healing progress was not satisfactory. In
the ES group (SWC + ES), WSA decreased at a mean rate of 44.8% a
week and closed 100% over a mean period of 7.3 weeks. In the
control group (SWC + sham ES), WSA decreased by an average of
28.9% over an average period of 7.4 weeks. The different polarity of
the treatment electrode used in the studies and slightly different
results obtained by their authors suggest that more clinical research
is needed to determine the wound healing efficacy of the cathode and
the anode.
Some progress has been made toward the creation of more
reliable guidelines on the use of the 2 electrodes in treating wounds in
humans. Having reviewed the results of in vitro and in vivo studies,
Kloth and Zhao30 have concluded that both these electrodes promote
wound healing and that the polarity of the treatment electrode should
enhance the cellular needs during the inflammatory and proliferative
phases of healing.
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The authors of in vitro studies31,32 have reported that anodal
stimulation facilitates electrotaxis of macrophages31 and neutrophilis32
for autolysis and reactivation of the inflammatory phase of healing.
Eberhardt et al.33 have demonstrated in vivo electrotaxis of
neutrophils toward the anode. The efficacy of anodal stimulation in
the early stages of wound healing has been recently confirmed from
in vivo studies with animals.34,35 Talebi et al.34 studied in vivo the
effect of anodal and cathodal ES (600 µA; 1 hour per day; 3 sessions
a week for a period of 3 weeks) on injury potential and wound size in
guinea pigs. They concluded34 that anodal ES was appropriate as a
means of improving the healing of acute skin wounds, because it
causes the wound surface to close and decreases healing time. The
Borba et al.35 randomized in vivo study with rats showed that anodal
stimulation (rectangular pulse current of 8 mA at a frequency of 7.7
pps) improved neoangiogenesis in the early stage of acute
experimental wound healing.
Cathodal ES has been found to enhance the proliferative phase
of wound healing. In vitro studies36–39 have demonstrated that in cell
cultures, human fibroblasts,36–38 keratinocytes,36 and bovine corneal
epithelial cells39 migrate directionally toward the cathode. The studies
imply that cathodal stimulation promotes granulation tissue
formation.36,38,40,41 The results of Bourguignon and Bourguignon’s41 in
vitro study with human fibroblasts indicated that HVMPC (twin-spike
pulses; 100 microseconds; 100 pps) could significantly increase the
rate of protein and deoxyribonucleic acid synthesis. They observed
that maximum synthesis of protein and deoxyribonucleic acid
occurred at 50 and 75 V in cells located adjacent to the negative
electrode. According to Zhao et al.39 the negative electrode can
effectively stimulate the epithelialization of wounds.
Asadi et al.42 found from in vivo research that cathodal sensorylevel ES increases the release of vascular endothelial growth factor
(VEGF) in skin. Their study was designed to evaluate the effect of
sensory (LIDC; 600 µA) and motor (monophasic current; pulse
duration 300 microseconds, 100 pps, 2.5–3.0 mA) cathodal ES on
VEGF release in muscle and skin in the wound site in 48 male
Sprague-Dawley rats randomly assigned to 2 experimental groups
and a control group (ES was not applied). A full-thickness skin incision
was made on each animal’s dorsal region. The experimental groups
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received ES for 1 hour for 3 or 7 days. The VEGF expression in muscle
and skin was measured on days 3 and 7 after surgical incision. On
day 3, VEGF levels did not differ among the groups. On day 7, the
periwound cutaneous VEGF levels were significantly higher in the
sensory-level stimulation group than in the other groups (P < .05).
No differences in VEGF were found in muscle tissue. These results led
Asadi et al.42 to conclude that the sensory-level cathodal ES increases
the release of VEGF in skin. This may explain why a negative current
applied at a sensory level can effectively promote the proliferative
phase of wound healing. In the clinical study by Franek et al.22
cathodal HVMPC (100 microseconds; 100 pps) was observed to
improve granulation tissue growth in VLUs. After 2 weeks of
treatment, the area of granulation tissue in the group receiving SWC
with compression therapy plus cathodal HVMPC was significantly
greater than in the control group where only compression therapy and
SWC were applied (P < .003).
The authors of the reviews of clinical studies5,43 and of
epidemiological studies44 point to wound closure as the most
important endpoint in evaluating the efficacy of wound treatment, but
in clinical studies with ES, treatment is rarely continued until wounds
close completely (in only 1 of the reviewed clinical studies were all
PrUs treated with HVMPC until full closure20), so the percentages of
wounds that closed after 4, 6, or 12 weeks of treatment are
frequently reported instead. In trials that end before wounds are
closed, the PAR of wounds after treatment in relation to baseline is
crucial,5,43,44 so in the majority of the reviewed studies, the wound
healing progress is expressed as PAR.20–27 Gilman45,46 has put forward
a formula (Gilman formula [GF]) for calculating the healing rate for
wounds of all shapes.

Aim Of Study
The aim of this clinical study was to establish whether a
cathodal HVMPC could improve the healing of chronic PrUs in older
adults with Stage II and III PrUs.
Based on research findings previously cited, the authors
formulated the following research hypothesis: that cathodal HVMPC is
capable of decreasing PrU surface area regardless of the wound shape
and can significantly accelerate the healing process.
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Methods
A prospective, randomized, double-blind clinical trial was
conducted with 2 groups of patients to compare the healing of PrUs
after 6 weeks of intervention involving SWC combined with cathodal
ES, as well as SWC with sham ES. Ethics approval for the experiment
was granted from the Academy of Physical Education in Katowice
Bioethics Commission. The study was registered in Australian New
Zealand Clinical Trials Registry (ANZCTR12614000207617).

Participants
Eligibility
Patients screened for the trial were hospitalized in 2 nursing
and care centers. The patient’s eligibility to participate in the study
was assessed by their physician based on the following criteria: older
than 60 years, at high risk of PrU development (<14 points on the
Norton scale), with a PrU of between 1.0 and 50 cm2 and duration
from 1 to 12 months. In order to make the comparable groups as
analogous as possible, only individuals with Stage II and III PrUs
(which are typically diagnosed in older adult patients) located on the
pelvic girdle (sacrum, coccyx, ischial tuberosity, trochanter major)
were included in the study.
The patients who did not qualify for ES (contraindications
include cancer, electronic implants; malignant, tunneling, and necrotic
wounds; osteomyelitis; PrU requiring surgical intervention; and metal
implants in the PrU area) were excluded from participating, as well as
those with diagnoses that might interfere with wound healing, such as
diabetes (HbA1c >7%), venous insufficiency, critical infection,
alcoholism, and allergy to standard wound treatment.

Demographic Information
Patient demographics were obtained from standard interviews,
physical examinations, and the history of concomitant diseases
contained in the patients’ medical records. Before the study began,
the Norton scale was used to assess the patients’ physical and mental
condition, the level of activity, mobility, and incontinence; with the
Braden scale, the risk of friction and shear, wound moisture, sensory
perception, physical activity, and mobility were determined. A
comprehensive review of the patients’ nutrition was also conducted,
Advances in Skin & Wound Care, Vol 29, No. 10 (October 2016): pg. 447-459. DOI. This article is © Wolters Kluwer Health,
Inc. and permission has been granted for this version to appear in e-Publications@Marquette. Wolters Kluwer Health,
Inc. does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express
permission from Wolters Kluwer Health, Inc.

9

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

including the assessment of factors that might influence dietary intake
and of the extent of nutrient and fluid losses. The nutritional status of
a patient was quantified by means of the Nutritional Risk Score (NRS
2002).47

Wound Severity
Wound severity at enrollment was established by the physician
using the National Pressure Ulcer Advisory Panel1 criteria (with Stage
II PrUs meaning partial-thickness loss of the dermis presenting as a
shallow open ulcer with a red-pink wound bed, no slough; and Stage
III PrUs meaning full-thickness tissue loss, subcutaneous fat may be
visible, but the bone, tendon, or muscle is not exposed).

Interventions
Wound Care Program Administered To Both Groups
Pressure ulcer prevention measures, wound care, and physical
treatment were administered to all patients using the same
prospective protocol and under the supervision of the main
investigator. Each patient was comprehensively assessed by an
interdisciplinary medical team to develop an individualized wound
prevention and treatment program consistent with best practices.1,2,48
The physicians assessed the general condition of the patients and
their PrUs, as well as developing treatment programs. When
necessary, neurologists, cardiologists, diabetes specialists, surgeons,
and other specialists were also consulted. The nurses gave care to the
patients, administered drugs, and applied dressings to wounds as
prescribed by the physicians. The physiotherapists created and
implemented kinesiotherapy programs for the patients. The
physiotherapists, nurses, and clinical caregivers were responsible for
applying measures to prevent the development of PrUs, including the
repositioning of the patients. The dietitians assessed the nutritional
status of the patients and developed therapies to make up for
nutritional deficiencies. The clinician caregivers were blinded to study
group assignments.
All patients received treatment to prevent the development of
additional PrUs. Pressure-redistribution surfaces, devices, and pillows
were provided as needed. Persons who could change position were
asked to do so as often as possible to relieve pressure on the ulcer
area. At least once every 2 hours, a nurse, physiotherapist, or clinical
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caregiver determined whether the patients had changed position. The
patients who could not move on their own were repositioned by a
nurse or physiotherapist.
Blood analysis was performed to screen for nutritional status
markers and metabolic disorders such as anemia (iron deficiency
anemia or anemia of chronic disease), thyroid dysfunction, impaired
glycemic control, dehydration, protein deficit, and hypoalbuminemia.
The attending physician regularly examined patients’ wounds to
determine what topical treatments were needed. Intervention
included tissue debridement, infection and inflammation control,
maintaining moisture balance, and the monitoring of wound edges
and the process of epithelialization. Wounds were cleaned with
antiseptics and then covered with hydrogel or hydrocolloid dressings
to trigger autolysis. Necrotic tissue was cleaned enzymatically, and
infected wounds were rinsed with antiseptics. When bacterial infection
was suspected (presence of fever, leukocytosis, high level of Creactive protein, and/or redness and inflammatory infiltration around
the wound) patients were administered antibiotics. Wounds were
treated with topical dressings appropriate for the stage of wound
healing, the depth of the wound, the presence of infection, and the
presence of exudates, and wound intensity. Cleaned wounds with
granulation tissue and moderate exudate were covered with dressings
moistened with 0.9% sodium chloride, hydrocolloid, or polyurethane
foam dressings. Wounds showing necrotic tissue and wounds with
considerable exudate were covered with hydrogel dressings or
alginate dressings. All immobilized patients received low-molecularweight heparin as a standard therapy.

Electrical Stimulation
In addition to SWC, patients in the ES group and in the control
group both received active HVMPC and sham HVMPC.
The HVMPC device was the Intelect Advanced Combo unit
(model 2771 by Chattanooga Group, Vista, California), which was set
to generate a twin-peak monophasic pulse (154 microseconds)
consisting of two 77-microsecond exponential pulses in rapid
succession. The pulse frequency was 100 pps, and the peak electric
current was usually 0.24 amperes (A), so it induced only sensory
perception in the patients without any motor reactions. The voltage
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was set to 100 V, and the charge delivered by the electrodes was 250
microcoulombs (µC) per second. This protocol was adopted because
of the positive results of earlier clinical trials on patients with
PrUs20,21,26,27 and VLUs.22,24 The patients participated in 5 sessions of
50 minutes in length per week (Monday through Friday) according to
the protocols used in other studies.20–22,26,27
All patients were treated in the same way using identical
stimulators that had 2 independent circuits for delivering electrical
current; according to the study protocol, only 1 circuit was active. The
electrical current parameters (pulse duration and shape, frequency,
and voltage) and the duration of the procedure were displayed on the
monitor so that patients in both groups could see them, but in the
control group, the electrodes were connected to the inactive electrical
circuit. The person in charge of connecting the electrodes to the
appropriate circuit (active or passive) was the facility chief
physiotherapist, who did so in an inconspicuous manner to prevent
the patient, the physiotherapist in charge of the procedure, and other
members of the medical team (physicians, nurses, caregivers) from
knowing whether real or sham ES was applied.
Each patient was provided with his/her own set of conductive
carbon-rubber electrodes. The treatment electrode (5.0 × 10.0 cm)
was placed on an aseptic gauze pad saturated with physiological
saline overlying the wound site. The return electrode (10.0 × 10.0
cm) closing the electrical circuit was placed on a gauze pad saturated
with physiological saline and applied to healthy skin at least 20 cm
from the PrU.
Pressure ulcers were stimulated with the cathode during each
daily treatment period, as in the clinical studies on PrUs21 and VLUs.24
The preclinical studies36–40 have shown that the cathode can enhance
fibroblast and epithelial cell motility and stimulate granulation tissue
growth and reepithelialization.
Before and after each procedure, the electrodes were sterilized
in disinfectant solutions (Incidin Liquid and Sani-Cloth Active; Ecolab,
Monham am Rhein, Germany). The PrUs were thoroughly cleansed
with a 0.9% sodium chloride solution and covered with the
aforementioned dressings as soon as the procedure was complete.
In both groups, the healing of PrUs was monitored for 6 weeks
or until wounds closed, whichever occurred first. This specific length
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of observation was imposed by the duration of patient stay in nursing
and care centers (6 weeks on average).
In patients with more than 1 PrU, all wounds were treated, but
only the most severe wound was analyzed statistically.

Outcomes
Primary Outcome
The primary outcome in both groups was percentage reduction
in WSA in relation to the baseline at week 4 (PAR4) and at week 6
(PAR6) enabling the comparison of wound healing progress between
the groups.

Secondary Outcomes
The secondary outcomes were as follows:
1. the value of GF45,46 for comparing wound healing progress
regardless of wound shape;
2. average percentage change in wound area by weeks 1 through
6 of treatment (PAR/week 1, PAR/week 2, PAR/week 3,
PAR/week 4, PAR/week 5, PAR/week 6), calculated to
determine in which week WSA decreased the most; and
3. percentages of PrUs in which WSA closed or increased (relative
to the baseline), which were calculated after 6 weeks of
intervention.

Sample Size
Group sizes appropriate for the study were established through
a pilot study. Because results were obtained from the random pilot,
the sample had unimodal distribution with skewness and flatness
below 2.5. Thus, the arithmetic average and standard deviation (SD)
were accepted as reliable measures of central value and dispersion.
Based on type I error, probability [alpha] = .05 and test power 1 [beta] = .90 were selected. An assumption was made that for wound
healing progress to be statistically significant the improvement
against the baseline must be at least 20% in both groups. The groups
were initially assumed to consist of at least 48 randomly selected
patients (24 in a group), but to allow for dropouts, 60 participants
were finally selected.
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Randomization/Blinding
After the included patients, or their legal guardians as
appropriate, granted their written consents to participate in the
study, they were randomly allocated between the ES group (SWC
plus active HVMPC) and the control group (SWC plus sham HVMPC)
using a concealed process (Figure 1). The allocation procedure did
not consider who was to receive and when to deliver the treatment.
The randomization schedules were constructed with blocks of 2
to ensure equal distribution of patients across the 2 groups. The
allocation sequence was concealed by using sealed envelopes with
consecutive numbers. After baseline measurements of the patients,
the main investigator opened the envelopes one at a time in the
presence of the principal physiotherapist, and the particular patient
was directed to the indicated group.
All patients, physicians, care providers, and physiotherapists, as
well as the person making weekly measurements of WSA and the
statistician processing the data, were blinded. The only person
engaged in the experiment who was not blinded was the principal
physiotherapist, who set the devices to apply active or sham ES.

Measures and Statistical Methods
Before the study commenced and at the end of each week of
treatment, 7 measurements were taken to establish each patient’s
WSA (in cm2). For all PrUs that closed before the end of week 6, the
date of closure was recorded. A wound was defined as closed when its
surface area decreased to 0 cm2.
The WSA for all patients was measured by a blinded person who
used the same method as that used in several other clinical
trials.22,26,27 After the contours of wounds were transferred onto
transparent film, they were measured with the planimeter to establish
the WSA. The data obtained were processed by a digitizer (Mutoh
Kurta XGT; Altek, Liberty Lake, Washington) connected to a personal
computer (C-GEO version 4.0; Instrumenty Geodezyjne Thadeusz
Nadowski, Tychy, Poland), which was also used for storing the results.
Measurement errors arising from different wound shapes
ranged between 2.7% (for PrUs of 60–70 cm2) and 37.9% (PrUs <1
cm2). The errors were calculated with the following formula: [DELTA]S
/ S = I × [DELTA]r / S, where [DELTA]S / S is the relative error of the
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wound area measurement method; [DELTA]S is the absolute error of
area measurement; I is a wound perimeter; [DELTA]r is the absolute
error related to the thickness of the plotting pen (0.2 mm) and to the
digitizer’s cross-hair (0.1 mm); r = 2 × 0.2 mm + 0.1 mm. A detailed
discussion of the method used to calculate measurement errors is
provided in the authors’ earlier study.26
Both PAR4 and PAR6 were calculated in the following way:
The GF was:
The percentage change in wound area at weeks 1 through 6
were calculated as follows:
The statistical analysis was performed by a blinded person
using the Statistica software (version 10.0; StatSoft Polska Sp. z o.o,
Krakow, Poland). Patient characteristics were checked for normal
distribution using the Shapiro-Wilk W test. When the distributions
were found not to be normal, nonparametric tests were applied to
evaluate the results of the study. The distributions of patient
characteristics were tested for skewness, kurtosis, and modality.
Because skewness and kurtosis were in all cases smaller than 4, and
the distributions were unimodal, a mean and an SD were used to
measure the central value and dispersion.
Both comparative groups were tested for the homogeneity of
patient characteristics using the 2-sided Fisher exact test and the
Mann-Whitney U test. The Mann-Whitney U test was also used to
compare mean percentage change in WSA and the values of GF
between the groups and to establish the statistical significance of
differences in weekly healing rates between the groups. The
percentages of PrUs that closed or increased in size were compared
between the groups after 6 weeks of treatment using the 2-sided
Fisher exact test. In all cases, the level of significance was set at P
< .05.

Results
Participant Flow
Between November 1, 2013, and December 30, 2014, 72
patients were screened for participation in the study. Twelve of those
patients were not randomized to receive treatment, and 11 of the
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remaining 60 patients (18.33%) dropped out before the end of the 6week treatment period (Figure 1).

Baseline Data
Tables 1 and 2 contain the demographic and wound
characteristics of 49 patients in 2 groups who completed the study.
There were no statistically significant differences between the groups
regarding any variable measured at the baseline.
The patients were treated in 2 nursing and care centers that
strived to prevent the development of PrUs and treated the wounds
according to the same standards. The sample of patients consisted of
37 women (75.51%) and 12 men (24.49%) ranging in age from 60 to
95 years, but mostly older than 80 years (n = 27; 55.1%). All
patients scored on the Norton scale below 14 points. Thirty-nine
patients (79.59%) were immobile, or their mobility was very limited.
Thirty-four patients (69.39%) received a diagnosis of generalized
atherosclerosis, 19 (38.77%) had type 2 diabetes (HbA1c <7%), and
19 (38.77%) were affected by a cerebral stroke.
The patients had a total of 49 PrUs that ranged in size from
1.18 to 38.34 cm2; 22 PrUs were Stage II (44.9%), and 27 were
Stage III (55.1%). Of the 49 PrUs, 25 (51.02%) were located in the
sacral region, 17 (34.69%) on the ischial tuberosity, and 7 (14.28%)
on the trochanter. Eleven patients (22.45%) had multiple PrUs, and in
23 patients (46.94%), recurring PrUs were diagnosed. The duration of
the PrUs before the clinical trial began was 1 to 12 months, with most
lasting 1 to 3 months (n = 37; 75.51%).

ES Group
The ES group consisted of 25 patients, 19 women and 6 men,
at a mean age of 79.92 years (range, 60–92 years). Two patients
(8%) were obese (body mass index [BMI], >30 kg/m2), and 4 (16%)
were underweight (BMI <19 kg/m2). Twenty patients (80%) could not
change position unless assisted. Sixteen patients (64%) had general
atherosclerosis, 11 (44%) had diabetes (HbA1c <7%), and 9 (36%)
were affected by cerebral strokes. This group was diagnosed with a
total of 25 PrUs, of which 13 (52%) developed in the sacral region, 8
(32%) on the ischial tuberosity, and 4 (16%) on the trochanter.
Fourteen PrUs (56%) were Stage III, and 11 (44%) were Stage II.
Their average duration was 2 months (range, 1–10 months), but most
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of them (n = 19; 76%) developed less than 3 months before the
study began. Six patients (24%) had more than 1 PrU, the largest of
which was monitored for healing.

Control Group
The control group consisted of 24 patients, 18 women and 6
men, at a mean age of 76.33 years (the range was 60–95 years).
Three patients (12.5%) were obese (BMI >30 kg/m2), and 2 (8.33%)
were underweight (BMI <19 kg/m2). Twenty patients (80%) needed
assistance to change position. Eighteen patients (75%) had general
atherosclerosis, 8 (33.33%) had diabetes (HbA1c <7%), and 10
(41.67%) were affected by cerebral stroke. These patients had a total
of 24 PrUs, of which 12 (50%) were located in the sacral region, 9
(37.5%) on the ischial tuberosity, and 3 (12.5%) on the trochanter.
Thirteen PrUs (54.17%) were Stage III, and 11 (45.83%) were Stage
II. Their average duration was 2.81 months (range, 1–12 months),
but most of them (n = 18; 75%) developed less than 3 months
before the study commenced. Five patients (20.83%) had more than
1 PrU, of which the largest was monitored for healing.

Primary Outcomes
At week 1 of treatment, the PAR in the ES group was
statistically significantly greater than that in the control group (35%
± 30.5% compared with 17.07% ± 34.13% in the control group; P
= .032). The ES group maintained its advantage over the control
group for the next 2 weeks (Figure 2). At week 4 of treatment, PAR4
was greater in the ES group (mean ± SD, 71.64 ± 33.74%) than in
the control group (44.21 ± 48.58%), but it was not statistically
significant (P = .064). In the next 2 weeks, wounds healed in both
groups but at different paces. As a result, PAR6 was significantly
greater in the ES group (mean ± SD, 80.31 ± 29.02%) than in the
control group (mean ± SD, 54.65 ± 42.65%) at P = .046 (Figure 2).

Secondary Outcomes
The GF calculated for the ES group was significantly greater
(0.95 ± 0.5 compared with 0.57 ± 0.52 in the control group; P
= .015) (Table 3).
In the ES group, the largest decreases in WSA were observed
at weeks 1, 2, and 3, by 35%, 32.78%, and 45%, respectively. In
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the control group, the rates were 17.07%, 12.78%, and 20.32%,
respectively. At weeks 1 and 2, the differences were statistically
significant and always in favor of the ES group (P = .032, P = .044)
(Figure 3).
The ES group had higher percentages of Stage II and III PrUs
that closed (respectively, 9 of 11 [45%] and 3 of 14 [17.65%]) than
the control group (6 of 11 [35.29%] and 1 of 13 [6.25%]), but the
differences were not statistically significant (at P = .74 and P = .6)
(Table 3).
Pressure ulcers did not increase in size in any of the patients
treated with ES, whereas in the control group, 2 Stage III PrUs were
larger relative to the baseline (P = .22) (Table 3).

Discussion
The results of this clinical trial confirmed the research
hypothesis that HVMPC accelerates the healing of Stage II through III
PrUs. Ulcers managed with HVMPC in addition to SWC decreased
statistically significantly more than those in the control group (SWC
alone). In all patients, WSA decreased the fastest in the first 4 weeks
of treatment. In weeks 5 and 6, the surface area of PrUs decreased at
a slower rate. The PAR was significantly greater in the ES group than
in the control group in all weeks but week 4. The GF showed that
regardless of their shape PrUs treated with a combination of SWC and
HVMPC were decreasing significantly faster than were those receiving
SWC alone. Unlike the ES group, where not a single PrU increased in
size, in the control group, 2 Stage III PrUs were larger than at
baseline. These results are consistent with the results obtained by
other researchers who treated PrUs with HVMPC.21,22,25–27
Study patients received a diagnosis of Stage II (44.9%) and III
PrUs (55.1%). Other investigators applied HVMPC to treat Stage II,
III, and IV PrUs in spinal cord–injured patients,21,25 older adult
patients,20,27 and patients immobilized for long periods owing to
orthopedic injury.26 This study, as well as other studies,21,25–27
confirms that HVMPC can be effectively applied to treat PrUs.
Given that patients in this study had comorbid diseases that
could stimulate the development of new PrUs or interfere with the
healing of the existing ones, it was not expected that all their wounds
would close over the 6 weeks of intervention. Accordingly, the
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percentage decrease in WSA relative to its baseline measurement
(PAR) was taken as the primary research outcome. Special attention
was given to PAR4 and PAR6. Percentage area reduction after 4
weeks is reported by many authors of clinical trials,20–27 and the
authors of the reviews of clinical studies5,43 and epidemiological
studies44 consider it a predictor of PrU healing within 12 to 20 weeks.
Percentage area reduction after 6 weeks was calculated to establish
the degree of wound healing that could be achieved by applying
cathodal HVMPC for 6 weeks.
In 15 randomized controlled trials analyzed by Koel and
Houghton,5 4 weeks of ES with monophasic electric current decreased
Stage II-IV PrUs by 37.02% to 69.21%, but in the control groups
(SWC alone or SWC plus sham ES), the decrease ranged from 6.77%
to 44.04%. In this study, Stage II and III PrUs treated with HVMPC
were smaller at week 4 by an average of 71.64% versus 44.21% in
the control group, so these results are comparable with the results
reported by Koel and Houghton.5
Having analyzed retrospectively the effects of topical wound
care on 306 VLUs and 241 DFUs, Cardinal44 found PAR4 to predict the
probability of wound closure in 12 weeks. For PAR4 = 37.7%, the
positive predictive value for complete closure was 70.6%, and the
likelihood ratio was 6.15, meaning that the odds of total closure in 12
weeks were 6.15 times greater for wounds with PAR4 of at least
37.7% than for wounds with smaller PAR4. Considering Cardinal’s44
results, PAR4 of 71.64% obtained in this study for the ES group
allows the authors to predict that PrUs would have closed in 12
weeks.
In this trial, at week 6 of treatment, the baseline area of Stage
II and III PrUs in the ES group was smaller by 80.31%. The results of
other authors who also used HVMPC were very similar. Six weeks of
HVMPC intervention in Franek et al.26 and Polak et al.27 studies on 26
Stage II and III PrUs25 and 10 Stage II and III PrUs27 resulted in a
PAR of 88.9% and 92.67%, respectively. In Kloth and Feedar’s
study,20 9 Stage IV PrUs healed completely during 7.3 weeks. Griffin
et al.21 recorded an 80% decrease in Stage II through IV PrUs after
20 successive days of treatment. Houghton et al.25 who applied
HVMPC to Stage II through IV PrUs, recorded that they were smaller
in size by 70.0% at week 12.
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Wound closure is another important surrogate endpoint in
clinical trials indicated in reviews.43 The patients treated in this study
did not stay in the care facilities long enough for the authors to
observe them until all wounds closed. However, 6 weeks was
sufficient for 9 of 11 Stage II PrUs (45%) and 3 of 14 Stage III PrUs
(17.65%) treated with HVMPC + SWC to close. These observations
suggest that HVMPC must be applied to older adult patients longer
than 6 weeks for Stage II and III PrUs to close. Houghton et al.25
noted that 12 weeks of HVMPC + SWC therapy caused all Stage II
PrUs to close, but only 5 of 15 Stage III through IV PrUs (30%). The
authors concluded that 12 weeks of intervention with HVMPC + SWC
was sufficient for Stage II PrUs to close, but in the case of more
severe PrUs, longer application of ES combined with SWC might be
necessary to achieve the same result. The study of Houghton et al.25
does not provide an indication of how long ES should be applied for
Stage III and IV PrUs to close, as the study was not long enough.

Methodology of ES with HVMPC
The HVMPC treatment protocol used in this study was similar to
that used by other authors.20–27 In all cases, the sterilized treatment
electrode was placed on the wound, and the return electrode was
attached to intact periwound skin approximately 15 to 20 cm from the
wound edge. Both electrodes were separated from tissue by sterile
gauze pads moistened with physiological saline. These measures
maintained a moist wound environment and enhanced the flow of
electric signal through the wound.
The available literature does not indicate what parameters
make electric current particularly useful in treating different types of
soft tissue wounds, but HVMPC in the voltage range from 100 to 150
V that the authors of this study as well as other authors used to treat
PrUs,20,21,25–27 VLUs,22,24 and DFUs23 has been demonstrated to be
effective. The amperage that was selected in this study (0.24 A)
following other research protocols20–27 caused only sensory sensations
in the patients, without evoking motor responses from the muscles.
As in other studies,23–30 the study used the HVMPC twin-peaked
monophasic pulses of 154 microseconds and a frequency of 100 pps.
The authors of most studies involving HVMPC applied it to PrUs
for 45 to 60 minutes, once a day, 5 to 7 days a week, so the total
duration of ES ranged from 3.75 to 7 hours per week.20–22,24,26,27 The
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treatment sessions in this study were similar in duration: 50 minutes
per day, 5 days per week, resulting in a total treatment time per
week of 4.16 hours.
Reports from trials indicate that wound healing can be
enhanced by several current waveforms, but Kloth49 maintains that it
is the electrical charge energy (charge quantity delivered to the
wound) that determines the dosage that is the best to promote
wound healing. According to Kloth’s review of clinical studies,49 ESs
with LVMPC and HVMPC using an electrical charge of 250 to 500
µC/second can effectively advance the healing of chronic wounds.
Some authors of clinical studies have not stated the value of the
electrical charge they used. They set the charge at the sensory level
below muscle contraction (visible or palpable) by asking the patients
about their sensations. In this study, an electrical charge of 250
µC/second was adopted, the smallest of those recommended for
wound treatment, because the patients were unable to describe how
they felt the current. Because of the characteristics of electrical
impulses, amperage had to be set to 0.24 A so that an electrical
charge of 250 µC/second could be obtained. In the pretrial tests, an
amperage of 0.24 A was well tolerated by healthy patients, but larger
dosages made some complain.
The application of cathodal stimulation in this study is
supported by evidence from preclinical studies36–40 and has previously
been reported by authors treating pressure22 and VLUs.24 Based on a
review of the results of preclinical and clinical studies, Kloth and
Zhao30 recommend using cathodal stimulation to improve the healing
of noninfected wounds as long as regular wound measurements,
increased granulation, and decreased exudation indicate that wound
healing is steadily progressing. When wound measurements show that
healing is not progressing or is regressing, polarity should be changed
to positive and maintained as long as healing progress continues. If
healing progress is observed to stop, polarity should be changed
again and maintained for 7 to 14 treatments as long as healing
progress is being made. In this study, cathodal HVMPC considerably
decreased the WSA of PrUs in the first 3 weeks of treatment, by 35%,
32.78%, and 45.68%, respectively (in the same period, healing rates
in the control group were 17.07%, 12.78%, and 20.32% a week). In
the next weeks of cathodal stimulation, WSA continued to decrease,
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although at a slower rate than in the early stage of treatment. This
study does not answer the question about whether switching cathodal
stimulation to anodal after 3 weeks would have enabled PrUs to heal
as fast. Further clinical research seems necessary to obtain more
information on this matter.
The groups of patients in this study were similar at the baseline
regarding the key determinants of wound healing, such as age,
wound duration, severity, and initial size. The groups consisted of
older adult patients (most of whom were >80 years old) at high risk
of PrU development, who had many comorbid conditions, such as
systemic atherosclerosis, diabetes, protein deficit, hemoglobin deficit,
lymphocytes deficit, and so on. Notwithstanding these unfavorable
circumstances, the applied treatment proved effective. Patients
receiving ES participated also in an interdisciplinary wound
management program as recommended by the best practice
guidelines on PrU treatment.1,2

Adverse Effects
Neither in this study nor in the trials conducted by other
investigators has HVMPC been found to have adverse effects.

Study Limitations
Because this study focused on patients with Stage II and III
PrUs, the results do not predict the outcomes should cathodal HVMPC
be used to treat Stage IV PrUs.
The 6-week treatment program (determined by average length
of patient stay in the facility) was not long enough for all PrUs to heal.
Consequently, it is not possible to conclude how long HVMPC should
be applied for Stage II and III PrUs to close. Results enabling the
evaluation of the long-term efficacy of PrU treatment are not
presented for several reasons; primarily, after the trial ended some
patients were discharged and returned to their homes or were
transferred to other wards to be treated for concomitant diseases.
The PrU prevention and treatment program was designed for
both groups based on the same best practice recommendations,2,48
but particular solutions were adapted to meet the needs of individual
patients. This customization may have contributed to differences in
PrU healing between groups.
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Conclusions
This research has shown that HVMPC (154 microseconds, 100
pps, 100 V, 250 µC/second) applied at a sensory level (50 minutes a
day, 5 times a week) using the cathode as the treatment electrode is
particularly effective in treating Stage II and III PrUs. This type of ES
reduced the surface area of Stage II and III PrUs and accelerated
their healing.
The results of the study are consistent with those obtained by
other researchers who have found HVMPC to improve the healing of
chronic wounds, including PrUs.

Suggestions for Further Research
Further RCTs are necessary to establish the efficacy of anodal
and cathodal HVMPC applied independently and consecutively, as well
as to determine the optimal parameters of this electric field signal.
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Image Gallery

Figure 1. Flow Diagram of The Study Process
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Table 1. Baseline Patient And Wound Characteristics (N = 49)

Table 2. Baseline Characteristics Of Pressure Ulcers (N = 49)

Figure 2. Cumulative Percentage Change In Wound Surface Area Calculated After
Each Week Of Treatment
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Table 3. Comparison Of Wound Outcomes Between Groups (N = 49)

Figure 3. Percentage Change In Wound Surface Area Calculated For Each Week Of
Treatment
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